The research subsidiary of biopharmaceutical firm Huons Global said it has filed for a patent on the manufacturing method of its human genetic recombinant hyaluronidase candidate.
Huonslab's HLB3-002, a human genetic recombinant hyaluronidase candidate, produced meaningful results confirming its efficacy, the Korean company said Tuesday.
Korea JoongAng Daily Sitemap